PMID- 36792176
OWN - NLM
STAT- MEDLINE
DCOM- 20230530
LR  - 20230530
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 70
IP  - 5
DP  - 2023 May 29
TI  - A questionnaire-based survey of medical conditions in adults with Prader-Willi 
      syndrome in Japan: implications for transitional care.
PG  - 519-528
LID - 10.1507/endocrj.EJ22-0561 [doi]
AB  - Prader-Willi syndrome (PWS) is a multisystem disorder with increased mortality 
      predominantly due to obesity-associated complications; therefore, the management 
      of obesity has been centric to therapeutic strategies for PWS. Although a 
      multidisciplinary team approach has been successful for this purpose during 
      childhood, it is generally difficult to implement during adulthood because of the 
      lack of a structured transitional care program. A more detailed understanding of 
      the current medical conditions of adults with PWS is needed to establish this 
      program; however, limited information is currently available on this issue in 
      Japan. Accordingly, we performed a questionnaire-based survey on 425 patients 
      with PWS. There were 162 adult patients aged 18 years or older with median body 
      mass indexes (kg/m(2)) of 29.4 and 30.4 in males and females, respectively. The 
      frequencies of type 2 diabetes mellitus (T2DM) and hypertension in adults with 
      PWS were 40.4 and 19.4%, respectively. Growth hormone (GH) therapy during 
      childhood correlated with lower rates of T2DM and hypertension during adulthood. 
      Among adult patients, 54% were treated by pediatricians, whereas 44% were seen by 
      internists with an endocrinologist/diabetologist being the most prevalent. Adult 
      patients treated with GH during childhood showed a higher rate of being seen by 
      pediatricians than those without, demonstrating that the multidisciplinary team 
      approach, typically applied with GH therapy, may be continuously provided even 
      after they reach adulthood. These results emphasize the importance of the 
      seamless provision of the multidisciplinary team approach, which is of clinical 
      importance for establishing an optimal transitional care program for PWS.
FAU - Kawai, Masanobu
AU  - Kawai M
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Department of Gastroenterology, Nutrition, and Endocrinology, Osaka Women's and 
      Children's Hospital, Izumi 594-1101, Japan.
AD  - Department of Bone and Mineral Research, Research Institute, Osaka Women's and 
      Children's Hospital, Izumi 594-1101, Japan.
FAU - Muroya, Koji
AU  - Muroya K
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, 
      Yokohama 232-8555, Japan.
FAU - Murakami, Nobuyuki
AU  - Murakami N
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Department of Pediatrics, Dokkyo Medical University Saitama Medical Center, 
      Koshigaya 343-8555, Japan.
FAU - Ihara, Hiroshi
AU  - Ihara H
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Department of Psychiatry, Dokkyo Medical University Saitama Medical Center, 
      Koshigaya 343-8555, Japan.
FAU - Takahashi, Yutaka
AU  - Takahashi Y
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Department of Diabetes and Endocrinology, Nara Medical University, Kashihara 
      634-8521, Japan.
FAU - Horikawa, Reiko
AU  - Horikawa R
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Division of Endocrinology and Metabolism, National Center for Child Health and 
      Development, Tokyo 157-8535, Japan.
FAU - Ogata, Tsutomu
AU  - Ogata T
AD  - Research Committee on Clinical Management of Prader-Willi syndrome, Research on 
      Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 
      Tokyo, Japan.
AD  - Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
AD  - Department of Pediatrics, Hamamatsu Medical Center, Hamamatsu 431-3192, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230314
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Adult
MH  - *Prader-Willi Syndrome/complications/epidemiology/therapy
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Japan/epidemiology
MH  - *Transitional Care
MH  - Obesity/complications
MH  - *Human Growth Hormone/therapeutic use
MH  - Growth Hormone
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Obesity
OT  - Prader-Willi syndrome
OT  - Transitional care
OT  - Type 2 diabetes mellitus
EDAT- 2023/02/16 06:00
MHDA- 2023/05/30 06:42
CRDT- 2023/02/15 20:53
PHST- 2023/05/30 06:42 [medline]
PHST- 2023/02/16 06:00 [pubmed]
PHST- 2023/02/15 20:53 [entrez]
AID - 10.1507/endocrj.EJ22-0561 [doi]
PST - ppublish
SO  - Endocr J. 2023 May 29;70(5):519-528. doi: 10.1507/endocrj.EJ22-0561. Epub 2023 
      Mar 14.